[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-carcinoma-of-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-carcinoma-of-lung":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644063","characterization-of-multi-omics-landscapes-and-ai-pathological-prediction-model-for-long-term-survival-in-nsclc-immunotherapy-100644063",false,"NCT07668037","Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy","Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed advanced or locally advanced non-small cell lung cancer (NSCLC).\n* Patients derived from real-world data of multiple centers (including Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital of Shanxi, Chinese Academy of Medical Sciences \\[Shanxi Cancer Hospital\\]; and other participating centers) or from completed phase III clinical trials (e.g., Choice-01, Rationale-307, Rationale-304).\n* Patients who received first-line or later-line immune checkpoint inhibitor (ICI) monotherapy or ICI-based combination therapy.\n* Patients with complete clinical information and available follow-up data.\n\nExclusion Criteria:\n\n* Patients whose systemic therapy did not include an immunotherapy regimen.\n* Patients lost to follow-up.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.",[24,25,26],"Non-Small Cell Carcinoma of Lung","Immunotherapy","Advanced Non-Small Cell Lung Cancer","RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-25","ACTUAL",{"date":33,"type":31},"2026-05-01",{"date":35,"type":20},"2030-05-01",{"name":37,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100633627","cardiopulmonary-exercise-testing-in-lung-cancer-patients-before-and-during-oncological-treatment-100633627","NCT07529145","Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment","Assessment of Respiratory Parameters and Physical Performance in Patients With Lung Cancer Qualified for Oncological Treatment Before and During Therapy, With Special Consideration of Cardiovascular Risk: A Cardiopulmonary Exercise Testing Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed lung cancer (any stage)\n* Qualified for standard oncological management (surgery and\u002For systemic therapy)\n* WHO\u002FECOG performance status 0-2\n* Ability to perform cardiopulmonary exercise testing (CPET)\n* Written informed consent\n\nExclusion Criteria:\n\n* Unstable ischemic heart disease\n* Symptomatic cardiac arrhythmias\n* Myocarditis or pericarditis\n* Decompensated heart failure\n* Active deep vein thrombosis\n* Suspected aortic dissection or severe aortic stenosis\n* Poorly controlled asthma\n* Resting oxygen saturation ≤ 85% on room air\n* Clinically relevant treatment-related adverse events above mild intensity (as applicable)\n* Any medical condition that, in the investigator's opinion, precludes safe participation in CPET\n* Withdrawal of informed consent",{"count":48,"type":20},90,"Patients with lung cancer often have reduced physical fitness and coexisting health problems, which may limit their ability to tolerate oncological treatment. Standard resting lung and heart tests do not always reflect real-life physical capacity during everyday activities or physical effort.\n\nThis observational study aims to assess cardiorespiratory fitness in patients with lung cancer before and during standard oncological treatment using cardiopulmonary exercise testing (CPET). CPET is a safe, supervised exercise test that provides objective information on how the heart, lungs, and muscles respond to physical effort.\n\nParticipants with WHO\u002FECOG performance status 0-2 will undergo CPET before treatment initiation and again after the early phase of therapy or surgery. The results may help identify patients with reduced physiological reserve and support individualized monitoring during routine clinical care.",[24,51],"Small Cell Carcinoma of Lung",[53,54,55,56,57],"lung cancer treatment","cpet","V02peak","ventilatory efficiency","cardiopulmonary exercise testing","2026-04-07",{"date":60,"type":31},"2026-04-14",{"date":62,"type":31},"2026-01-01",{"date":64,"type":20},"2027-09-01",{"name":66,"class":38},"Medical University of Bialystok",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100630087","fiber-boost-randomized-controlled-trial-100630087","NCT07483112","Fiber-Boost Randomized Controlled Trial","Multicenter, Randomized, Controlled Trial to Study the Effects of a High-Fiber Dietary Intervention on ctDNA Clearance and the Microbial and Immunological Landscape in Patients With Advanced Non-Small Cell Lung Cancer Receiving PD-1\u002FPD-L1-Targeted Monotherapy (Fiber-Boost)","Fiber-Boost","Inclusion Criteria:\n\n* Age ≥18 years\n* Written informed consent according to Swiss law and ICH\u002FGCP regulations before inclusion and prior to any trial-specific procedures\n* Histologically or cytologically confirmed NSCLC\n* Advanced or recurrent NSCLC not amenable to curative treatment\n* PD-L1 expression ≥50% (TPS) determined by an approved IHC test\n* No actionable genetic alterations in genes such as EGFR, ALK, ROS1, HER2, BRAF, RET, MET, NTRK\n* First-line palliative PD-1\u002FPD-L1-targeted monotherapy at a 3-weekly schedule indicated per local investigator\n* Willingness and ability to undergo study interventions\n* ECOG performance status 0-2\n* Adequate organ function:\n* Hemoglobin ≥70 g\u002FL, platelet count ≥50 G\u002FL, granulocytes ≥1 G\u002FL\n* Bilirubin, ALT, AST ≤3 x ULN\n* Glomerular filtration rate (Cockroft-Gault) ≥30 mL\u002Fmin\u002F1.73m²\n* Measurable or evaluable disease per RECIST 1.1\n* Patients with CNS metastases are eligible, provided there is no requirement for corticosteroids as therapy for CNS disease and no evidence of clinical progression\n* Women with child-bearing potential use effective contraception (two independent methods), are not currently pregnant or lactating, and agree to not become pregnant during the trial treatment and during 3 months thereafter. A negative pregnancy test in either urine or blood is required for women with child-bearing potential before trial inclusion.\n* Men who are not sterile agree to use contraceptive methods (condoms) or abstain from sexual intercourse during the trial treatment and 3 months thereafter.\n\nExclusion Criteria:\n\n-History of malignancy, unless in remission for at least 3 years before inclusion with the exception of pT1-2 prostate cancer Gleason score \\\u003C6, adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer\n\nAdjuvant or additive systemic ICB treatment within 6 months prior to inclusion\n\n* Systemic treatment with an antibiotic within 10 days of ICB treatment\u002FHFD intervention start\n* Concomitant immunosuppressive drugs including corticosteroids at a daily dose of ≥10mg prednisone equivalents, methotrexate, azathioprine, TNF-α inhibitors\n* Concurrent treatment with other experimental drugs or other anticancer therapy\n* Major surgical procedures within 14 days prior to inclusion as judged by the investigator\n* Active autoimmune disease requiring systemic immunosuppressive treatment that is seen as contraindication for the use of PD-1\u002FPD-L1-targeted monoclonal antibodies\n* Uncontrolled diabetes mellitus\n* Severe or uncontrolled cardiovascular disease\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications\n* Had an allogeneic tissue\u002Fsolid organ transplant\n* Ongoing supplementation with OptiFibre® or another fiber supplement",{"count":76,"type":20},42,"INTERVENTIONAL",[79],"NA","In the present study 'Fiber-Boost', we investigate how a high-fiber diet affects the immunotherapy of advanced lung cancer and what effects it has on the gut microbiome (i.e., the bacteria in the gut) as well as the immune system. Study participants will be assigned to either a test group or a control group. Only patients in the test group will undergo a high-fiber diet. The study lasts 6 weeks per patient and will be conducted at 4 centers within Switzerland. A total of 42 patients are planned to be included in the study.",[24],[83,84,85,86],"non-small cell lung cancer","immunotherapy","high-fiber diet","microbiome","2026-03-16",{"date":89,"type":31},"2026-03-19",{"date":91,"type":31},"2025-10-07",{"date":93,"type":20},"2027-12-31",{"name":95,"class":38},"Cantonal Hospital of St. Gallen",4]